No Data
XOMA Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains XOMA Corp(XOMA.US) With Buy Rating, Raises Target Price to $123
XOMA Royalty Shares Are Trading Higher After the Company Announced Its Economic Interest in Seralutinib, a Phase 3 Asset Studying Pulmonary Arterial Hypertension.
Express News | XOMA Royalty Corp - Phase 3 Study for Pulmonary Arterial Hypertension Is Ongoing and Is Expected to Read Out in Q4 of 2025
Express News | XOMA Royalty Corp - Potential to Net up to $25 Mln in Milestone Payments and Earn a Low to Mid-Single Digit Royalty
Press Release: XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
